Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 29, 16 January 2024
Open
Access | Article
Sequence and structure statistics of the nanobody database and molecular dynamics simulation analysis of the nanobody VHH
* Author to whom correspondence should be addressed.
Abstract
Antibodies are immunoglobulins produced in vivo by immune cells stimulated by exogenous molecules, and nano-antibodies are a class of molecules that are similar to conventional antibodies but smaller in size. Originally discovered as an antibody in camelidsand cartilaginous fishes, they are called heavy chain antibodies due to the lack of light and heavy chain constant regions in the CH1 region except for the retained heavy chain, and their binding region to the antigen consists of the heavy chain variable region only, making them the smallest antibodies available with complete antibody functional properties. In this experiment, we analyzed the commonalities and differences of the nanobodies by extracting all their amino acid sequences, performed protein modeling of the relevant nanobodies of coronaviruses among them, and then analyzed the data of RMSD and RMSF by using molecular dynamics simulation, and finally predicted and analyzed the protein conformation and the structures of VHH at all levels.
Keywords
nanobodies, molecular dynamics simulation, protein modeling
References
1. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature, 1993, 363: 446-8
2. Muyldermans S, Atarhouch T, Saldanha J, et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng, 1994, 7: 1129-35
3. Stanfield RL, Dooley H, Flajnik MF, et al. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science, 2004, 305: 1770-3
4. Muyldermans S, Atarhouch T, Saldanha J, et al. Sequence andstructure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains[J]. Protein Engineering, 1994, 7(9):1129-1135.
5. Muyldermans S. Nanobodies: natural single - domain antibodies[J]. Annual Review of Biochemistry, 2013, 82(1) : 775 - 797
6. Hassanzadeh － Ghassabeh G, Devoogdt N, De Pauw P, et al． Nano-bodies and their potential applications［J］．Nanomedicine, 2013, 8( 6) : 1013 － 1026
7. LI Jingying, LI Zhiwei, Xiao Shuqi. Nanobodies and disease control[J]. Advances in Animal Medicine, 2021, Vol.42 (8): 112-116
8. Jovčevska, Ivana, Muyldermans, Serge. The Therapeutic Potential of Nanobodies. [J]. BioDrugs, 2020, Vol. 34(1): 11-26
9. De Genst ESilence K, Decanniere K, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies[J]. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103(12): 4586-4591.
10. Sun Baihe, Wu Yue, Zhao Rui, Lou Yuxin, Li Wanting, Li Yanfei, Ma Linlin. Progress of therapeutic nanobodies with different expression systems [J/OL]. Chinese Journal of Bioengineering.
11. Wrapp D, De Vlieger D, Corbett K S, et al. Structural basis for po-tent neutralization of betacoronaviruses by single - domain camelid antibodies[J]. Cell, 2020, 181(5) : 1004 - 1015. e15．
12. Jianbo Dong, Betty Huang, Zhejun Jia, Bo Wang, Sachith Gallolu Kankanamalage, Allison Titong, Yue Liu. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity[J]. Emerging microbes & infections,2020,Vol.9(1): 1034-1036
13. Zhou Huihui, CHEN Qu, Yang Xiaomei et al. Research progress of nanobodies in cancer therapy[J]. Life Science,2022,34(04):468-476.
14. Su, Benchao. Research on the construction of an immunosensing system based on nanobodies and two-dimensional nanomaterials for the detection of human serum alpha-fetoprotein [D]. Hainan University,2022
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-279-4
- ISBN (Online)
- 978-1-83558-280-0
- Published Date
- 16 January 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/29/20240615
- Copyright
- © 2023 The Author(s)
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited